Elevated troponin-I after percutaneous coronary interventions: incidence and risk factors

Cardiovasc Radiat Med. 2004 Apr-Jun;5(2):59-63. doi: 10.1016/j.carrad.2004.05.001.

Abstract

Background: Percutaneous coronary interventions (PCIs) are often complicated by postprocedural myocardial necrosis as manifested by elevated cardiac markers.

Purpose: To assess the incidence and risk factors of elevated troponin-I (TnI) after PCI.

Methods and results: We performed a retrospective analysis on 522 PCI cases over a 1-year period at a single center. An elevated postprocedural TnI (>1.0 ng/ml) occurred in 213 patients (40.8%). Overall, glycoprotein (GP) IIb/IIIa inhibitors were used in 52% of cases. Baseline clinical characteristics were similar between the positive and the negative TnI groups. A univariate analysis revealed that patients with elevated TnI post-PCI had significantly more multivessel (28% vs. 15%, P = .001) and multilesion interventions (44% vs. 27%, P<.0001). The lesions were longer, more often angulated and involving bifurcations, and more complex in the TnI-positive group. Stent use and number of stents was higher in the TnI-positive group, and longer inflation times (>30 s) or higher inflation pressures (>14 atm) were used more often in the TnI-positive group. GP IIb/IIIa inhibitor use was higher in the TnI-positive group (61% vs. 45%, P = .0007). After multivariable analysis, independent predictors of elevated TnI after PCI included multilesion intervention, lesion length, lesion angulation, and GP IIb/IIIa inhibitor use.

Conclusion: TnI is elevated in approximately 40% of cases after PCI. TnI is more likely to be elevated after intervention on multiple lesions, angulated or long lesions.

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary / adverse effects*
  • Female
  • Heart Diseases / epidemiology*
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Necrosis / epidemiology
  • Necrosis / etiology
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Predictive Value of Tests
  • Retrospective Studies
  • Risk Factors
  • Stents / statistics & numerical data
  • Troponin I / blood*

Substances

  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Troponin I